Last reviewed · How we verify

LUM — Competitive Intelligence Brief

LUM (LUM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tankyrase inhibitor / Wnt signaling modulator. Area: Gastroenterology.

marketed Tankyrase inhibitor / Wnt signaling modulator Tankyrase (TNKS1/TNKS2) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

LUM (LUM) — Vertex Pharmaceuticals Incorporated. LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LUM TARGET LUM Vertex Pharmaceuticals Incorporated marketed Tankyrase inhibitor / Wnt signaling modulator Tankyrase (TNKS1/TNKS2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tankyrase inhibitor / Wnt signaling modulator class)

  1. Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LUM — Competitive Intelligence Brief. https://druglandscape.com/ci/lum. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: